Billionaire Ken Griffin Sold Amazon and Nvidia but Quietly Loaded Up on This Healthcare Giant

Citadel Advisors increased its stake in Intuitive Surgical by 30.3% in Q1, despite the stock falling 20% over the past 12 months amid competition, tariffs, and lower-margin product ramps. The article argues the company’s wide moat, large addressable robotic-assisted surgery market, and potential AI-driven improvements support a long-term bullish case. The piece is more of an investment thesis than a fresh catalyst, so near-term price impact should be limited.

Analysis

The cleaner read is not simply “buy the dip in ISRG,” but that the market is likely underestimating how competition behaves in a category with extreme installed-base inertia. New robotic entrants can win headlines and some procedure share, yet the economics are usually delayed: hospitals already invested in training, service contracts, and workflow integration are biased toward staying put unless a rival proves materially better on outcomes and utilization. That means the nearer-term loser is likely not ISRG’s core franchise, but the expectations gap for recent entrants and adjacent healthcare hardware names that need to spend heavily for years before seeing operating leverage.

The real second-order effect is margin mix. A company like ISRG can afford to compress near-term unit margins on newer systems if it expands the base that drives recurring instruments and service revenue; that is a classic installed-base land grab. Investors focused on current product margins may miss that the valuation should be tied more to multi-year recurring pull-through than to this year’s hardware ASPs, especially when the addressable market is still early in adoption. If the current replacement cycle and procedure growth continue, the market could re-rate the stock before margin expansion is fully visible.

Tariff pressure is a legitimate near-term overhang, but it is more likely to show up as a timing issue than a thesis breaker. The company can typically offset input shocks through phased pricing and mix optimization over several quarters, whereas competitors with weaker pricing power will feel the same cost inflation more acutely. That creates a subtle winner/loser spread: ISRG can defend economics, while less established rivals face a harder path to subsidizing sales and installations.

The contrarian point is that this is not a cheap stock because it is not a cyclical stock. The proper question is whether the market is paying for optionality on AI-enabled procedural workflow and a still-early robotic surgery penetration curve; on that basis, the recent drawdown may be more of a reset in sentiment than a true deterioration in franchise value. The risk is that competitive launches create a long period of “good enough” alternatives, which could cap multiple expansion even if fundamentals remain solid.

Key Decisions for Investors

• Long ISRG on a 3-6 month horizon; use weakness to build position, with upside driven by sentiment normalization and recurring revenue visibility rather than near-term margin expansion.
• Pair trade: long ISRG / short MDT over the next 6-12 months; ISRG has more operating leverage to installed-base growth, while MDT faces the harder task of converting product launches into durable platform economics.
• Avoid chasing JNJ or other broad med-tech proxies as a pure RAS beta expression; they have less torque to robotic adoption and more exposure to slower-moving healthcare mix.
• If you want convexity, consider ISRG call spreads 6-12 months out; target a setup where the market rerates the stock before full margin benefits show up, limiting premium at risk.
• Use any tariff-driven selloff as an add signal only if procedure growth remains intact; if utilization weakens, the thesis shifts from temporary cost pressure to demand elasticity, which would be a bigger red flag.